← Back to Search

Unknown

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

Phase 1
Waitlist Available
Research Sponsored by Technoderma Medicines Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 42 days

Summary

This trial tests a new scalp solution, TDM-105795, for treating hair loss in men aged 18-55 with Androgenetic Alopecia. Participants will use the solution regularly to see if it helps grow hair or stop further loss.

Eligible Conditions
  • Male Pattern Baldness

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~42 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 42 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidence rate of any local and systemic AEs
Number of participants with abnormal ECG readings
Number of participants with abnormal echocardiogram results
+3 more
Secondary study objectives
Plasma concentrations of TDM-105795

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: MAD Cohorts 1-4 TDM-105795 topical solutionExperimental Treatment1 Intervention
Multiple dose administration of TDM-105795 Topical Solution, 0.0025% or 0.005% or 0.01% or 0.02%
Group II: Placebo for TDM-105795 topical solutionPlacebo Group1 Intervention
Multiple dose administration of Placebo forTDM-105795 Topical Solution
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TDM-105795
2021
Completed Phase 1
~70

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Technoderma Medicines Inc.Lead Sponsor
4 Previous Clinical Trials
183 Total Patients Enrolled
Therapeutics, Inc.Industry Sponsor
30 Previous Clinical Trials
3,880 Total Patients Enrolled
Daniel Piacquadio, M.D.Study DirectorTherapeutics Incorporated
2 Previous Clinical Trials
440 Total Patients Enrolled
~8 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top